From: Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis
Treatment naive (n = 1244) | Previously treated with another DMT (n = 270) | Recently treated with another DMT (n = 247) | Overall population (N = 1702)a | |||||
---|---|---|---|---|---|---|---|---|
Placebo (n = 586) | Teriflunomide 14 mg (n = 658) | Placebo (n = 131) | Teriflunomide 14 mg (n = 139) | Placebo (n = 89) | Teriflunomide 14 mg (n = 158) | Placebo (N = 806) | Teriflunomide 14 mg (N = 896)a | |
Age, mean (SD) years | 38.8 (9.0) | 37.9 (9.2) | 37.5 (8.6) | 37.9 (8.4) | 36.4 (9.5) | 39.0 (9.6) | 38.3 (9.0) | 38.0 (9.1) |
Female gender, n (%) | 414 (70.6) | 458 (69.6) | 105 (80.2) | 103 (74.1) | 65 (73.0) | 114 (72.2) | 584 (72.5) | 634 (70.8) |
White, n (%) | 518 (88.5)b | 595 (90.4) | 124 (94.7) | 131 (94.9)c | 84 (94.4) | 154 (97.5) | 726 (90.2)d | 821 (91.7)e |
Time since diagnosis of MS, mean (SD) years | 4.42 (5.73) | 4.40 (5.55)f | 6.83 (4.92) | 8.00 (5.55) | 5.85 (5.26) | 6.18 (6.04) | 4.97 (5.62) | 5.24 (5.85)e |
Time since first symptoms of MS, mean (SD) years | 7.79 (7.28) | 7.49 (6.74)f | 9.26 (5.63) | 10.90 (6.87) | 8.79 (7.02) | 9.39 (7.19) | 8.14 (7.02) | 8.26 (6.91)e |
Number of relapses within past year, mean (SD) | 1.40 (0.71)g | 1.37 (0.69)h | 1.42 (0.87)i | 1.36 (0.81)j | 1.49 (0.81)k | 0.90 (0.88)l | 1.42 (0.75)m | 1.37 (0.71)n |
Baseline EDSS score | ||||||||
Mean (SD) | 2.61 (1.37) | 2.57 (1.33) | 2.97 (1.32) | 2.79 (1.37) | 2.58 (1.37) | 2.49 (1.38) | 2.67 (1.37) | 2.64 (1.34) |
Median (min, max) | 2.50 (0.0, 6.0) | 2.50 (0.0, 6.5) | 3.00 (0.0, 6.0) | 2.50 (0.0, 6.0) | 2.50 (0.0, 5.5) | 2.00 (0.0, 6.5) | 2.50 (0.0, 6.0) | 2.50 (0.0, 6.5) |
Last prior DMT,o,p n (%) | ||||||||
Fingolimod | 0 | 1 (4.5) | 1 (0.8) | 3 (2.2) | 0 | 0 | 1 (0.4) | 4 (1.5) |
GA | 6 (27.3) | 4 (18.2) | 42 (32.1) | 51 (36.7) | 33 (37.1) | 27 (17.1) | 81 (33.5) | 82 (31.5) |
IFNBq | 0 | 0 | 3 (2.3) | 0 | 2 (2.2) | 2 (1.3) | 5 (2.1) | 2 (0.8) |
IFNB-1a | 11 (50.0) | 9 (40.9) | 57 (43.5) | 55 (39.6) | 36 (40.4) | 110 (69.6) | 104 (43.0) | 115 (44.2) |
IFNB-1b | 5 (22.7) | 8 (36.4) | 27 (20.6) | 27 (19.4) | 18 (20.2) | 19 (12.0) | 50 (20.7) | 54 (20.8) |
Natalizumab | 0 | 0 | 1 (0.8) | 3 (2.2) | 0 | 0 | 1 (0.4) | 3 (1.2) |